Our technology identifies individuals at increased risk of developing diseases related to Neu5Gc consumption. By analyzing antibody repertoire scores and Neu5Gc intake, the method predicts disease likelihood and provides tailored dietary recommendations to reduce risk.

Unmet Need
Neu5Gc, a non-human sialic acid present in red meat and dairy, has been implicated in chronic inflammatory conditions and cancer. Current diagnostic approaches lack precision in correlating dietary Neu5Gc intake with disease risk, leaving a gap in preventive healthcare strategies.

Our Solution
Our diagnostic system evaluates anti-Neu5Gc antibody repertoires in human biological samples. By comparing these scores against a control value, the method predicts risks associated with Neu5Gc consumption. It also integrates dietary data to provide personalized recommendations, aiding disease prevention.

Video:

Unique Advantages
1. Predictive Accuracy: Antibody repertoire score offers precise risk prediction for diseases like cancer and cardiovascular conditions.
2. Personalized Prevention: Provides specific dietary guidelines to minimize Neu5Gc-related risks based on individual consumption habits.
3. Broad Application: Effective for various Neu5Gc-related disorders, including cancer and other chronic inflammatory diseases.
4. Non-Invasive Testing: Utilizes blood samples, making it user-friendly and suitable for regular health assessments.
Potential Applications
1. Clinical Diagnostics: Early identification of individuals at risk for cancer, atherosclerosis, and other inflammatory diseases.
2. Preventive Healthcare: Tailored dietary recommendations to reduce disease likelihood.
3. Nutritional Research: Supporting studies on the impact of diet on chronic disease development.

Reference:
Association between Neu5Gc carbohydrate and serum antibodies against it provides the molecular link to cancer: French NutriNet-Santé study | BMC Medicine | Full Text

Patent:
ASSESSMENT OF DISEASE RISK FACTORS IN CORRELATION WITH NEU5GC INGESTED IN FOOD, National phase, WO 2020/255134